Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., . . . Gonzalez, E. E. (2012). Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. The lancet oncology, 13(3), 300-308. https://doi.org/10.1016/S1470-2045(11)70385-0
Chicago-Zitierstil (17. Ausg.)Ciuleanu, Tudor, Lilia Stelmakh, Saulius Cicenas, Skaidrius Miliauskas, Alexandru Calin Grigorescu, Carina Hillenbach, Hrefna Kristin Johannsdottir, Barbara Klughammer, und Emilio Esteban Gonzalez. "Efficacy and Safety of Erlotinib Versus Chemotherapy in Second-line Treatment of Patients with Advanced, Non-small-cell Lung Cancer with Poor Prognosis (TITAN): A Randomised Multicentre, Open-label, Phase 3 Study." The Lancet Oncology 13, no. 3 (2012): 300-308. https://doi.org/10.1016/S1470-2045(11)70385-0.
MLA-Zitierstil (9. Ausg.)Ciuleanu, Tudor, et al. "Efficacy and Safety of Erlotinib Versus Chemotherapy in Second-line Treatment of Patients with Advanced, Non-small-cell Lung Cancer with Poor Prognosis (TITAN): A Randomised Multicentre, Open-label, Phase 3 Study." The Lancet Oncology, vol. 13, no. 3, 2012, pp. 300-308, https://doi.org/10.1016/S1470-2045(11)70385-0.